Literature DB >> 8148365

Angiotensin converting enzyme inhibitors as potential cognitive enhancing agents.

A M Domeney1.   

Abstract

Anecdotal reports of a mood-elevating effect in patients and improvements in the performance of memory tests in the clinic has led to investigations into the nootropic actions of angiotensin converting enzyme (ACE) inhibitors. A cognitive enhancing action for the ACE inhibitors has been demonstrated in a number of animals models of memory function. Neurochemical studies in animals have shown that angiotensin II acting via an angiotensin II receptor can inhibit the release of 3HAch from entorhinal cortex slices. Thus the ability of ACE inhibitors to facilitate cognitive processes may be related to reduced availability of angiotensin II. Lack of specificity of ACE inhibitors may be a limiting factor in the development of such compounds as cognitive enhancers. However, the recent development of selective antagonists for subtypes of the angiotensin II receptor may represent a novel approach for the treatment of cognitive disorders with an underlying cholinergic disturbance.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8148365      PMCID: PMC1188561     

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  43 in total

1.  Distribution of angiotensin II receptors in the brain of nonhuman primates.

Authors:  M A Millan; D M Jacobowitz; K J Catt; G Aguilera
Journal:  Peptides       Date:  1990 Mar-Apr       Impact factor: 3.750

2.  Identification of angiotensin II receptor subtypes.

Authors:  A T Chiu; W F Herblin; D E McCall; R J Ardecky; D J Carini; J V Duncia; L J Pease; P C Wong; R R Wexler; A L Johnson
Journal:  Biochem Biophys Res Commun       Date:  1989-11-30       Impact factor: 3.575

3.  Angiotensin converting enzyme in rat brain visualized by quantitative in vitro autoradiography.

Authors:  S Y Chai; F A Mendelsohn; G Paxinos
Journal:  Neuroscience       Date:  1987-02       Impact factor: 3.590

4.  Comparison of enalapril and atenolol in mild to moderate hypertension.

Authors:  A L Herrick; P C Waller; K E Berkin; S D Pringle; J S Callender; M P Robertson; J G Findlay; G D Murray; J L Reid; A R Lorimer
Journal:  Am J Med       Date:  1989-04       Impact factor: 4.965

5.  Nootropic effects of ACE inhibitors in mice.

Authors:  C Mondadori; P Etienne
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

6.  Psychotropic effects of angiotensin II and III in rats: locomotor and exploratory vs cognitive behaviour.

Authors:  J J Braszko; K Wiśniewski; G Kupryszewski; B Witczuk
Journal:  Behav Brain Res       Date:  1987-09       Impact factor: 3.332

7.  Angiotensin II inhibits acetylcholine release from human temporal cortex: implications for cognition.

Authors:  J M Barnes; N M Barnes; B Costall; Z P Horovitz; J W Ironside; R J Naylor; T J Williams
Journal:  Brain Res       Date:  1990-01-22       Impact factor: 3.252

8.  Angiotensin II inhibits the release of [3H]acetylcholine from rat entorhinal cortex in vitro.

Authors:  J M Barnes; N M Barnes; B Costall; Z P Horovitz; R J Naylor
Journal:  Brain Res       Date:  1989-07-03       Impact factor: 3.252

9.  The effects of ACE inhibitors captopril and SQ29,852 in rodent tests of cognition.

Authors:  B Costall; J Coughlan; Z P Horovitz; M E Kelly; R J Naylor; D M Tomkins
Journal:  Pharmacol Biochem Behav       Date:  1989-07       Impact factor: 3.533

10.  Nonpeptide angiotensin II receptor antagonists. IV. EXP6155 and EXP6803.

Authors:  P C Wong; W A Price; A T Chiu; M J Thoolen; J V Duncia; A L Johnson; P B Timmermans
Journal:  Hypertension       Date:  1989-05       Impact factor: 10.190

View more
  1 in total

1.  PhenoPredict: A disease phenome-wide drug repositioning approach towards schizophrenia drug discovery.

Authors:  Rong Xu; QuanQiu Wang
Journal:  J Biomed Inform       Date:  2015-07-04       Impact factor: 6.317

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.